

A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis

Laurie L. Baggio,¹ Qingling Huang,¹ Theodore J. Brown,² and Daniel J. Drucker¹

Peptide hormones exert unique actions via specific G protein–coupled receptors; however, the therapeutic potential of regulatory peptides is frequently compromised by rapid enzymatic inactivation and clearance from the circulation. In contrast, recombinant or covalent coupling of smaller peptides to serum albumin represents an emerging strategy for extending the circulating $t_{1/2}$ of the target peptide. However, whether larger peptide-albumin derivatives will exhibit the full spectrum of biological activities encompassed by the native peptide remains to be demonstrated. We report that Albugon, a human glucagon-like peptide (GLP)-1–albumin recombinant protein, activates GLP-1 receptor (GLP-1R)-dependent cAMP formation in BHK-GLP-1R cells, albeit with a reduced half-maximal concentration (EC_{50}) (0.2 vs. 20 nmol/l) relative to the GLP-1R agonist exendin-4. Albugon decreased glycemic excursion and stimulated insulin secretion in wild-type but not GLP-1R^{−/−} mice and reduced food intake after both intracerebroventricular and intraperitoneal administration. Moreover, intraperitoneal injection of Albugon inhibited gastric emptying and activated c-FOS expression in the area postrema, the nucleus of the solitary tract, the central nucleus of the amygdala, the parabrachial, and the paraventricular nuclei. These findings illustrate that peripheral administration of a larger peptide-albumin recombinant protein mimics GLP-1R–dependent activation of central and peripheral pathways regulating energy intake and glucose homeostasis in vivo. *Diabetes* 53:2492–2500, 2004

From the ¹Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, Toronto, Ontario, Canada; and the ²Division of Reproductive Science, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and the University of Toronto, Toronto, Ontario, Canada.

Address correspondence and reprint requests to Dr. Daniel J. Drucker, Toronto General Hospital, Banting and Best Diabetes Centre, 200 Elizabeth St., MBRW4R-402, Toronto, Canada M5G 2C4. E-mail: d.drucker@utoronto.ca.

Received for publication 4 December 2003 and accepted in revised form 28 May 2004.

CCK, cholecystokinin; CNS, central nervous system; DPP-IV, dipeptidyl peptidase-IV; Ex-4, exendin-4; GLP, glucagon-like peptide; GLP-1R, GLP-1 receptor; HSA, human serum albumin; ICV, intracerebroventricular; IP, intraperitoneal; NTS, nucleus of the solitary tract.

© 2004 by the American Diabetes Association.

Glucagon-like peptide (GLP)-1 is a 30–amino acid peptide hormone secreted from gut endocrine cells in response to nutrient ingestion that promotes nutrient assimilation through regulation of gastrointestinal motility and islet hormone secretion (1). Infusion of GLP-1 into normal or diabetic human subjects stimulates insulin and inhibits glucagon secretion, thereby indirectly modulating peripheral glucose uptake and control of hepatic glucose production (2). GLP-1 also produces anorectic effects, and short-term infusion of GLP-1 is associated with diminished appetite and reduced energy consumption in normal, obese, and diabetic human subjects (3). Taken together, the actions of GLP-1 to reduce glycemia while preventing concomitant weight gain have attracted considerable interest in pharmaceutical approaches to enhancing GLP-1 action for the treatment of type 2 diabetes.

A major challenge for the therapeutic use of regulatory peptides, including native GLP-1, is a short circulating $t_{1/2}$, due principally to rapid enzymatic inactivation and/or renal clearance. Although infusion of native GLP-1 is highly effective in lowering blood glucose in subjects with type 2 diabetes, a single subcutaneous injection of the native peptide is quickly degraded and disappears from the circulation within minutes (4). Hence, the majority of pharmaceutical approaches to the development of GLP-1 mimetic agents have focused on the development of long-acting degradation-resistant peptides (5). The naturally occurring lizard salivary gland peptide exendin-4 (Ex-4) is a potent GLP-1 receptor (GLP-1R) agonist and exhibits therapeutic efficacy in studies of patients with type 2 diabetes (6). Similarly, a fatty acylated human GLP-1 analog, liraglutide, exhibits a more sustained duration of action and potentially reduces glycemic excursion in diabetic subjects (7).

Although degradation-resistant GLP-1R agonists appear to be promising agents for the treatment of diabetes, the need for once- or twice-daily injection of these peptides has fostered complementary efforts directed at identification of more potent longer-acting agents with sustained efficacy in vivo. Given the long circulating $t_{1/2}$ of albumin-linked drugs (8), a GLP-1–albumin protein should exhibit a much more prolonged circulating $t_{1/2}$ and hence requires a

reduced frequency of parenteral administration, relative to native GLP-1. Nevertheless, the molecular interaction with the GLP-1R, volume of distribution, and access to the central nervous system (CNS) would be predicted to be markedly different for a much larger albumin-based molecule (8).

Whether all of the desirable actions of native GLP-1, including the activation of the CNS centers regulating food intake and gastrointestinal motility, would be mimicked by a much larger GLP-1–albumin protein is currently unclear. Accordingly, we have examined the biological actions of Albugon, a recombinant GLP-1–human serum albumin (HSA) fusion protein, using a combination of cell line studies in vitro and both wild-type and GLP-1R^{-/-} mice in vivo.

RESEARCH DESIGN AND METHODS

Reagents. Tissue culture medium, serum, and G418 were purchased from Invitrogen (San Diego, CA). Forskolin and 3-isobutyl-1-methylxanthine were obtained from Sigma (St. Louis, MO). HSA and Albugon were provided by Human Genome Sciences (Rockville, MD). Ex-4 and exendin (9-39) were purchased from California Peptide Research (Napa, CA).

Measurement of cAMP. Baby hamster kidney (BHK) cells stably transfected with rat GLP-1R were generated and propagated in medium containing 0.05 mg/ml G418 as described previously (9). Before analysis, BHK-GLP-1R cells were grown to 70–80% confluence in 24-well plates in the absence of G418 at 37°C. Ex-4 and exendin (9-39) were dissolved in PBS, and cells were treated with control or test reagents in Dulbecco's modified Eagle's medium containing serum and 100 μ M 3-isobutyl-1-methylxanthine. Cells were incubated with 1 μ M exendin (9-39) or medium alone for 5 min at 37°C, followed by an additional 10-min incubation in the presence of increasing concentrations of Ex-4, HSA, or Albugon. All reactions were carried out in triplicate and terminated by the addition of ice-cold absolute ethanol. Cell extracts were collected and stored at –80°C until assayed. For cAMP determinations, aliquots of ethanol extracts were lyophilized, and cAMP levels were measured using a cAMP radioimmunoassay kit (Biomedical Technologies, Stoughton, MA).

Mice. All animal experiments were carried out in accordance with protocols and guidelines approved by the Toronto General Hospital Animal Care Committee. GLP-1R^{-/-} mice on the C57BL/6 genetic background, and age-matched (8- to 15-week-old male) wild-type C57BL/6 mice (Charles River Laboratories, Montreal, PQ) were maintained on a 12-h light/dark cycle and allowed free access to standard rodent food and water, except where noted. Wild-type mice were acclimated to the animal facility for a minimum of 1 week before analysis.

Glucose tolerance tests and measurement of plasma insulin. Oral or intraperitoneal (IP) glucose tolerance tests were carried out after an overnight fast (16–18 h). Glucose (1.5 mg/g body wt) was administered orally through a gavage tube or by injection into the peritoneal cavity. A blood sample was drawn from the tail vein at 0, 10, 20, 30, 60, 90, and 120 min after glucose administration, and blood glucose levels were measured using a Glucometer Elite blood glucose meter (Bayer, Toronto, Ontario, Canada). For plasma insulin determination, a blood sample (100 μ L) was removed from the tail vein during the 10- to 20-min time period after glucose administration and immediately mixed with a 10% volume of a chilled solution containing 5,000 KIU/ml Trasylol (Bayer), 32 mmol/L EDTA, and 0.1 nmol/L Diprotin A (Sigma). Plasma was separated by centrifugation at 4°C and stored at –80°C until assayed. Plasma insulin levels were measured using a rat insulin enzyme-linked immunosorbent assay kit (Crystal Chem, Chicago, IL) with mouse insulin as standard.

Measurement of plasma glucagon. After an overnight fast (16 h), mice were given an IP injection of 1 mg/kg HSA or Albugon. At 20 min after HSA or Albugon administration, mice were killed and cardiac blood was obtained and mixed with a 10% volume of a chilled solution containing 5,000 KIU/ml Trasylol, 32 mmol/L EDTA, and 0.1 nmol/L Diprotin A. Plasma was separated by centrifugation at 4°C and stored at –80°C until assayed. Plasma glucagon levels were measured using a glucagon radioimmunoassay kit (Linco Research, St. Charles, MO).

Feeding studies. For analysis of food intake, mice were fasted overnight (16–18 h), and control (PBS or HSA) or test (Ex-4 or Albugon) reagents were administered by intracerebroventricular (ICV) or IP injection. For ICV injections, mice were lightly anesthetized using isoflurane inhalation (Abbott Laboratories, Saint-Laurent, Quebec, Canada), and reagents were administered in a total volume of 5 μ L by injection into the lateral ventricles using a 2.5 mm $\times$ 30-gauge needle attached to a Hamilton syringe as described (10).

Mice were allowed to recover from the anesthetic (~10 min) before assessment of food intake. For IP injections, 100 μ L control or test reagent was injected into the peritoneal cavity. Immediately after ICV or IP injection, mice were weighed and then placed into individual cages containing preweighed rodent food, with free access to water. At 2, 4, 7, and 24 h after reagent administration, the food was reweighed and total food intake (g/g of body wt) was calculated.

Gastric emptying. The gastric emptying rate was determined as described (11). Briefly, mice were fasted overnight (18 h) and then allowed free access to preweighed rodent food for 1 h. After the 1-h refeeding, the remaining food was weighed and food intake was determined. Mice were then given IP injections of PBS, Ex-4 (0.17 mg/kg), HSA (2.7 mg/kg), Albugon (3 mg/kg), or cholecystokinin (CCK)-8 (4 μ g) and deprived of food for an additional 4 h. Mice were anesthetized with Somnotol (sodium pentobarbital solution; MTC Pharmaceuticals, Cambridge, Ontario, Canada), their stomachs were removed, and stomach content wet weight was determined. Gastric emptying rate was calculated using the following: gastric emptying rate (%) = [1 – (stomach content wet weight/food intake)] $\times$ 100.

Measurement of c-FOS activation in the murine CNS. The number of c-FOS immunoreactive neurons in specific brain regions was assessed quantitatively in both wild-type C57BL/6 and GLP-1R^{-/-} mice as described (12,13). Briefly, animals were given IP injections of PBS, Ex-4, HSA, or Albugon in a 100 μ L volume. At 10 and 60 min after injection, mice were anesthetized with Somnotol. All mice were perfused intracardially with ice-cold normal saline followed by 4% paraformaldehyde solution. Brains were removed immediately at the end of perfusion, kept in ice-cold 4% paraformaldehyde solution for 3 days, and then transferred to a solution containing paraformaldehyde and 10% sucrose for 12 h. Brains were cut into 25- μ m sections using a Leica SM2000R sliding microtome (Leica Microsystems, Richmond Hill, Ontario, Canada) and stored at –20°C in a cold cryoprotecting solution. Sections were processed for immunocytochemical detection of FOS using a conventional avidin-biotin-immunoperoxidase method (Vectastain ABC Elite Kit; Vector Laboratories, Burlingame, CA) as described (12). The FOS antibody (Sigma-Aldrich, Oakville, Ontario, Canada) was used at a 1:50,000 dilution. Brain sections corresponding to the level of the area postrema, the nucleus of the solitary tract (NTS), the central nucleus of the amygdala, and the parabrachial and paraventricular nuclei were defined according to the mouse brain atlas of Franklin and Paxinos (14) and selected for analyses.

Statistical analysis. All data are presented as means $\pm$ SE. Statistical significance was determined by ANOVA and Bonferroni post-test using Prism version 3.03 software (GraphPad Software, San Diego, CA). A *P* value <0.05 was considered to be statistically significant.

RESULTS

Albugon is a recombinant human protein that contains a dipeptidyl peptidase-IV (DPP-IV)-resistant human GLP-1 analog encoded in the same open reading frame as the HSA amino acid sequence. To evaluate whether the bioactive domain(s) of a much smaller peptide hormone could still recognize and functionally interact with its cognate receptor when constrained within a much larger heterologous protein, we examined whether Albugon activated GLP-1R in vitro. Albugon produced a dose-dependent stimulation of cAMP accumulation in BHK-GLP-1R cells that was significantly diminished by coincubation with the GLP-1R antagonist exendin (9-39) (Fig. 1). Nevertheless, Albugon was not as effective in activating the GLP-1R when compared with the much smaller more potent lizard-derived GLP-1R agonist Ex-4 (Fig. 1; EC₅₀ = 0.2 vs. 20 nmol/L for Ex-4 vs. Albugon, respectively).

These experiments demonstrate that the considerably altered peptide conformation that arises after insertion of GLP-1 sequences into a much larger albumin open reading frame does not eliminate the ability of essential GLP-1 motif(s) to recognize and activate GLP-1Rs. To ascertain whether circulating Albugon is capable of reaching key sites and activating GLP-1R-dependent actions in vivo, we carried out oral glucose tolerance testing in mice. Glycemic excursion was significantly reduced after parenteral Albugon administration to wild-type mice (Fig. 2A). Further-




FIG. 1. Albugon exhibits similar efficacy but lower potency than Ex-4 at the rat GLP-1R in vitro. A stable BHK cell line expressing the rat GLP-1R was pretreated for 5 min with 1 μ M exendin (9-39) [Ex(9-39)] or medium alone before a 10-min treatment with increasing concentrations of Ex-4, Albugon, or HSA. cAMP levels in lyophilized aliquots of cell extracts were measured by radioimmunoassay and used to calculate total cAMP content per well. Values are expressed as means $\pm$ SE and are representative of data from two independent experiments, each performed in triplicate. * P < 0.05, ** P < 0.01, *** P < 0.001 for Ex-4- vs. Albugon-treated cells.

more, the glucose-lowering properties of Albugon depended on a functional GLP-1 receptor because Albugon had no effect on blood glucose in GLP-1R^{-/-} mice (Fig. 2B). Consistent with the known actions of smaller GLP-1R peptide agonists, Albugon, at doses ranging from 0.1 to 10 mg/kg, markedly reduced glycemic excursion after not only oral but also IP glucose loading, in association with a significant increase in the insulin-to-glucose ratios (Fig. 3A and B). Albugon increased the levels of plasma insulin after an IP glucose challenge (Fig. 3C) but did not significantly reduce the levels of plasma glucagon in mice after an overnight fast (Fig. 3D). Taken together, these results demonstrate that Albugon lowers blood glucose and enhances insulin secretion through GLP-1R-dependent mechanisms in vivo.

Smaller 30- to 40-amino acid GLP-1R agonists, including native GLP-1, Ex-4, and liraglutide, have been shown to inhibit food intake, presumably via activation of central hypothalamic centers regulating satiety (15). To assess whether a much larger recombinant GLP-1-albumin protein would also exert anorectic effects, we studied food intake in normal mice after ICV or IP peptide administration. ICV Albugon significantly lowered food intake in mice (relative to the HSA control) in a dose-dependent manner, and this effect was detectable for up to 7 h (Fig. 4A) but was not sustained over the entire 24-h observation period. In contrast, Ex-4 exerted a more potent and sustained anorectic effect after ICV administration, with a highly significant reduction of food intake observed even at the end of the 24-h study period (Fig. 3).

The blood-brain barrier is relatively impermeable to larger proteins such as albumin under both normal physiological conditions and in the setting of diabetes (16,17). Although GLP-1Rs are expressed on hypothalamic neurons regulating satiety (18,19), whether GLP-1R agonists require direct access to the brain for activation of the central anorectic pathway remains uncertain (20). Accordingly, we examined whether Albugon would also exhibit anorectic effects after peripheral administration. Although lower doses of IP Albugon, 0.16–11 nmol/kg, did not affect food

intake, the highest dose tested (110 nmol/kg) reduced food intake at all time points studied, from 2 to 24 h after Albugon administration (Fig. 4C). In contrast, much smaller doses of Ex-4 significantly reduced food ingestion after IP administration in the same experiments (Fig. 4D). Hence, although Albugon is capable of exerting anorectic actions after both central and peripheral administration, it is less potent compared with the smaller GLP-1R agonist, Ex-4. To ascertain whether the anorectic actions of peripherally administered Albugon were due to the nonspecific effects of the larger amount of injected protein, we repeated the experiments using age- and sex-matched wild-type control and GLP-1R^{-/-} mice. Albugon reduced food intake at all time points in wild-type mice but had no effect on food intake in GLP-1R^{-/-} mice. These findings demonstrate that IP Albugon inhibits food intake in a GLP-1R-dependent manner.

GLP-1R agonists markedly inhibit gastric emptying (21), and gastric distension induces c-FOS in GLP-1-expressing neurons in the rat medulla (22). However, whether direct CNS access is required for either GLP-1R-dependent inhibition of food intake or gastric emptying has not been determined. The basal rate of gastric emptying was comparable in wild-type and GLP-1R^{-/-} mice (Fig. 5). Both Ex-4 and CCK-8 significantly inhibited gastric emptying in wild-type mice; however, CCK-8, but not Ex-4, also inhibited gastric emptying in GLP-1R^{-/-} mice. Similarly, Albugon potentially inhibited gastric emptying in wild-type but not in GLP-1R^{-/-} mice (Fig. 5).

The anorectic actions of small peptide GLP-1R agonists are associated with c-FOS activation in CNS centers





FIG. 2. Albugon lowers blood glucose in wild-type but not in GLP-1R^{-/-} mice. Oral glucose tolerance in wild-type GLP-1R^{+/+} (A) and GLP-1R^{-/-} (B) mice given IP injections of 5 mg/kg of HSA (○) or Albugon (ALB; ■) 60 min before an oral glucose load. Values are expressed as means $\pm$ SE; n = 5–6 mice/group. ** P < 0.01, *** P < 0.001 for Albugon- vs. HSA-treated mice.



coupled with the control of energy intake (18,20,23). To determine whether peripherally administered Albugon was capable of activating neuronal FOS expression, we examined the pattern and extent of CNS FOS expression after IP Albugon administration. Ex-4 markedly increased c-FOS expression in the area postrema, the NTS, the central nucleus of the amygdala, the parabrachial nucleus, and the hypothalamic paraventricular nuclei (Fig. 6A-E). Similarly, Albugon significantly activated c-FOS expression in the identical brain regions, although much less robustly in the NTS and paraventricular nucleus than in

Ex-4 (Fig. 6A-E). Analysis of the murine CNS after peripheral (IP) administration of HSA did not detect immuno-reactive HSA in brain parenchyma (data not shown), consistent with the inability of HSA to rapidly cross the normal blood-brain barrier (8).

DISCUSSION

GLP-1-based therapies for type 2 diabetes are attracting increasing attention in part because of the preliminary efficacy demonstrated in clinical studies (6) and because




FIG. 4. Albugon (ALB) reduces food intake in fasted mice but is less anorectic than Ex-4. After an overnight fast, wild-type mice were given ICV (A and B) or IP (C–E) injections of PBS or increasing doses (nmol/kg) of Ex-4, HSA, or ALB. E: Wild-type and GLP-1R^{-/-} mice were fasted overnight and then given IP injections of 110 nmol/kg of HSA or ALB. Food intake was measured at 2, 4, 7, and 24 h after recovery from injection. Values are expressed as means $\pm$ SE; $n = 4$ –5 mice/group. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. control-treated (PBS or HSA) mice.

of unique yet complementary mechanisms of action (1). Unlike some antidiabetic agents that reduce blood glucose while promoting weight retention, GLP-1R activation is coupled with short-term inhibition of food intake in both rodent and human studies (15). Moreover, prolonged GLP-1 administration for 6 weeks to diabetic human subjects was associated with a significant reduction in body

weight over the study period (24). The anorectic properties of GLP-1 and its peptide analogs are thought to be due in part to both inhibition of gastric emptying and activation of central satiety centers coupled with reduction of energy intake (20,25). Although development of GLP-1-based small peptide analogs resistant to enzymatic inactivation is a major focus of current pharmaceutical activity




FIG. 5. Albugon (ALB) reduces the gastric emptying rate in wild-type but not GLP-1R^{-/-} mice. Gastric emptying rate in wild-type (WT) (A) and GLP-1R^{-/-} (B) mice at 4 h after IP administration of PBS, Ex-4 (0.17 mg/kg), HSA (2.7 mg/kg), ALB (3 mg/kg), or CCK octapeptide (CCK-8; 4 μ g/mouse) is shown. Values are expressed as means $\pm$ SE; $n = 3$ –4 mice/group. * $P < 0.05$, *** $P < 0.001$ vs. PBS; ## $P < 0.01$ vs. HSA.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.